{"id":2832,"date":"2025-02-06T14:22:23","date_gmt":"2025-02-06T11:22:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2832"},"modified":"2025-11-03T20:24:39","modified_gmt":"2025-11-03T17:24:39","slug":"percheron-therapeutics-announces-terminated-of-atl1102-study-for-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/zh\/percheron-therapeutics-announces-terminated-of-atl1102-study-for-dmd\/","title":{"rendered":"Percheron Therapeutics \u5ba3\u5e03\u7ec8\u6b62 ATL1102 \u6cbb\u7597 DMD \u7684\u7814\u7a76"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">\u201cOne way or other, we don\u2019t think ATL-1102 can remain the centerpiece of the story put forward to investors,\u201d Garner told investors in a webinar this morning.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: <a href=\"https:\/\/dmdwarrior.com\/percheron-disappointed-in-avicursen-atl1102-study-for-duchenne-dmd\/\">Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)<\/a>]<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"youtube-embed\" data-video_id=\"mSEmhOawVlc\"><iframe loading=\"lazy\" title=\"Webinar Recording \u2013 Phase IIb results discussion.\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/mSEmhOawVlc?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Read More<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clinical Trials for Duchenne (List of All Researches)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cOne way or other, we don\u2019t think ATL-1102 can remain the centerpiece of the story put forward to investors,\u201d Garner told investors in a webinar this morning. In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: Percheron Disappointed in Avicursen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2835,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[114,113,112,115],"class_list":["post-2832","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-atl1102","tag-avicursen","tag-percheron","tag-percheron-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/2832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/comments?post=2832"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/2832\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media\/2835"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media?parent=2832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/categories?post=2832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/tags?post=2832"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}